MF
ABUS icon

Magnetar Financial’s Arbutus Biopharma ABUS Stock Holding History

Magnetar Financial’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$263K Buy
+58,516
New +$256K ﹤0.01% 785

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Magnetar Financial's ABUS Position: Q1 2026 in Review

Magnetar Financial opened a new position in Arbutus Biopharma (ABUS) in Q1 2026: 58,516 shares worth $263K. The stake represents ﹤0.01% of the portfolio and ranks #785 among its holdings.

167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Magnetar Financial held 58,516 shares of Arbutus Biopharma worth $263K as of Q1 2026.
  • Arbutus Biopharma was a new Magnetar Financial position in Q1 2026.
  • Arbutus Biopharma made up ﹤0.01% of Magnetar Financial's portfolio in Q1 2026, its #785 holding.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Magnetar Financial's 13F filing for Q1 2026, filed 13 May 2026.